Abstract Purpose: Recent studies impressively showed the diagnostic potential of seroreactivity patterns for different tumor types, offering the prospect for low-cost screening of numerous tumor types simultaneously. One of the major challenges toward this goal is to prove that seroreactivity profiles do not only allow for identifying a tumor but also allow for distinguishing tumors from other pathologies of the same organ. Experimental Design: We chose glioma as a model system and tested 325 sera (88 glioma, 95 intracranial tumors, 60 other brain pathologies, and 82 healthy controls) for seroreactivity on a panel of 35 antigens. Results: We were able to discriminate between glioma and all other sera with cross-validated specificity of 86.1%, sensitivity of 85.2%, and accuracy of 85.8%.We obtained comparably good results for the separation of glioma versus nontumor brain pathologies and glioma versus other intracranial tumors. Conclusion: Our study provides first evidence that seroreactivity patterns allow for an accurate discrimination between a tumor and pathologies of the same organ even between different tumor types of the same organ.
Tumor antigens offer themselves as tumor markers for cancer detection. In spite of their undisputed usefulness, single tumor markers lack sufficient specificity and sensitivity. Recently, others and we have shown that antibody signatures of cancer patients' sera allow detection of various cancers. We reported for intracranial meningioma, a mostly benign tumor arising from the meninges covering the brain, that tumor patients' sera and normal sera can be separated with high specificity and sensitivity (1, 2) . Similar good separation has been achieved for patients with prostate cancer, lung adenocarcinoma, and non-small cell lung cancer (3 -5) . Most recently, two studies identified patients with ovarian cancer using antigen arrays (6, 7) . In the long-term, depending on the availability of informative antigens, seroreactivity pattern may achieve 100% sensitivity. In the future, this relatively low-cost technology may be developed into a platform for the regular screening of patients' risk groups. The approach also offers the prospect of testing several diseases simultaneously. In addition, it imposes less of a burden on the patients than some imaging technologies such as computer tomography.
One of the major challenges toward this goal is to prove that seroreactivity profiles do not only allow for distinguishing tumors from normal controls but also allow for tumors from other pathologies of the same organ. A seroreactivity profile indicative of a tumor may also be determined by another disease of the affected organ. To address this specific problem, we chose glioma and other brain pathologies as a model system. Although there are, as of yet, no clear risk groups known for glioma, we chose this tumor for the following reasons. Because of the blood-brain barrier, brain tumors are thought to be less immunogenic than other solid tumors. These circumstances make brain tumors a great challenge and a critical test case for the discrimination power of seroreactivity profiles. In addition, in previous studies, we have collected a reasonable number of tumor antigens immunogenic in intracranial tumors, especially in glioma.
Our study represents the first approach of applying antibody profiling simultaneously not only to a single tumor but also to various pathologies of the same organ. Using a panel of 35 antigens, we screened 325 sera including 88 sera from patients with astrocytic tumors, 82 sera from healthy donors, 95 sera from other intracranial tumors, and 60 sera from other neurologic diseases. We show that antibody profiling allows for an accurate discrimination not only between glioma patients' sera and normal sera but also between glioma sera, and sera of patients with other intracranial tumors (meningioma, pituitary adenoma, acoustic neurinoma, and metastatic tumor), and sera of patients with nontumor brain pathologies (multiple sclerosis, chronic inflammatory demyelinating polyradiculoneuropathy, and headache). Using standard 10-fold cross validation, we applied several well-known statistical learning approaches that yielded similar high specificity, sensitivity, and accuracy. By showing that seroreactivity profiles of glioma tumors differ from the profiles of other nontumor brain pathologies, and even from the profiles of other intracranial tumors, we provide first evidence that seroreactivity profiles have the potential to tell various diseases of single organs apart. This is a necessary prerequisite for developing seroreactivity patterns into new approaches for noninvasive or minimal invasive tumor diagnosis.
Materials and Methods
Tumor tissues and sera. Tumor tissues and blood samples of patients were obtained from the Departments of Neurosurgery and Neurology of Saarland University with patient's informed consent. The study has been approved by the local ethics committee. Tissue samples were frozen in liquid nitrogen immediately after surgery and stored at -70jC. All serum samples were isolated by centrifugation using serum gel monovettes and stored as aliquots at -70jC. Control samples of donors without known disease were recruited according to the following exclusion criteria: neurologic diseases, chronic diseases, cancer, persistent bacterial infections, and HIV and hepatitis B or C virus infections. Sera of glioma patients were collected from 1996 to 2004; sera from all controls were from 1996 to 2005. The mean age of glioma patients was 45.7 years; the mean age of controls 48.6 years. The difference between the age distributions was statistically not significant (Wilcoxon Mann-Whitney test) . The difference between gender distributions was likewise not statistically significant (Fisher's exact test). The mean seroreactivity is given for all sera, sera of glioma patients, normal sera, and sera of patients with other brain pathologies. The mutual information values of each antigen are given for the discrimination between glioma sera and the combined sera of all other groups, discrimination between glioma sera and sera of patients with other nontumor brain pathologies, discrimination between glioma sera and sera of patients with other intracranial tumors, and discrimination between glioma sera and normal sera.
cDNA expression library construction. Poly(A) RNA was isolated from tumor samples and used to construct the cDNA expression libraries in ZAP Express vector arms of E phage (Stratagene) as described previously (8) . cDNA expression libraries were constructed from a glioblastoma tissue, a pilocytic astrocytoma tissue, and a glioblastoma cell line.
Antigen identification. Standard SEREX was done as described previously (9) . In brief, serum was diluted 1:10 and preabsorbed five times by gravity flow using ''mechanical'' and ''lytical'' preabsorption columns. Mechanical preabsorption columns were assembled by incubating sonicated Escherichia coli XL1blue MRF ¶ cells in 1Â TBS with Affinity Adsorbent (glutaraldehyde activated; Boehringer Mannheim) in Bio-Rad Polyprep chromatography columns overnight. Lytical columns were prepared by using bacteria lysed by nonrecombinant ZAP Express phages. The preabsorbed serum was diluted to a final concentration of 1:100. E. coli XL1blue MRF ¶ cells were transfected with the cDNA expression library and plated to a density of f10,000 plaque-forming units/plate on NZCYM agar plates in presence of 12.5 Ag/mL tetracycline. Protein expression was induced and proteins were bound to nitrocellulose membranes. Membranes were blocked and incubated with preabsorbed patient serum and anti-human IgG antibody conjugated to alkaline phosphatase. Antigen-antibody complexes were detected by 0.005% (w/v) 5-bromo-4-chloro-3-indolyl phosphate and 0.01% (w/v) nitroblue tetrazolium in 1Â color developing solution. Serologic spot assays were done as described previously (10) . Before use, sera were preabsorbed against E. coli XL1blue MRF ¶ either by column purification as described previously or against plated transfected bacteria. In brief, nitrocellulose membranes were precoated with a layer of NZCYM/0.7% agarose/2.5 mmol/L IPTG and placed on a reservoir layer of NZCYM/0.7% agarose. Monoclonal phage and the cDNA library as control at a concentration of f5,000 plaque-forming units/AL were incubated with exponentially growing E. coli XL1blue MRF ¶ and spotted in duplicate on the precoated nitrocellulose membranes. After removal of the agarose film, membranes were incubated with individual serum samples. Autoantibodies were detected as described above. For each serum, at least two membranes were screened. An antigen was defined as ''positive'' if at least two of four replicates showed reactivity.
Statistical methods
Significance testing. The Wilcoxon Mann-Whitney test (11, 12 ) is a standard nonparametric hypothesis test for comparing two populations. It is applied to test the null hypothesis that two populations come from the same distribution versus the alternative hypothesis that the populations differ with respect to their location. If not mentioned otherwise, the P values were determined by unpaired twosample Wilcoxon Mann-Whitney tests. We applied the nonparametric Wilcoxon Mann-Whitney test instead of the parametric t test because the analyzed data were not normally distributed. To estimate the significance of the presented classification results, we computed P values using permutation tests by randomly permuting the class labels 1,000 times and by computing the classification accuracy. Here, the P value was computed via z scores. Classification. We applied several well-known statistical learning methods including linear discriminant analysis, diagonal discriminant analysis, support vector machines (SVM), and Naive Bayes (NB) classifiers. All methods were evaluated using standard 10-fold crossvalidation. The NB approach offers easily interpretable results. It computes for a serum S the quotient Q of the conditional probabilities that S is a control serum or a glioma serum, given the antigen pattern. The smaller this quotient, the more likely S is a glioma serum. We classify a serum as glioma serum, if Q is V1. To evaluate the classification results, we did standard 10-fold cross-validation. In brief, the data set was randomly split in 10 equally sized parts. Each of the 10 parts was used once as test set, whereas the other 9 parts were the training sets. Because different partitions in test and training set led to different classification results, we did 100 repeated cross-validation runs and computed the median of the results. All statistical analyses were carried out using the ''Seroreactivity Pattern Classification System'' (13).
Results
Antigen panel and selected sera. For accurate classification of autoantibody profiles, sufficiently large sets of antigens are necessary prerequisites. We compiled a panel of 35 antigens to classify seroreactivity profiles of glioma sera versus sera of other intracranial tumors and nontumor brain pathologies. In total, we analyzed f1,500,000 clones in a primary screening with patient sera. A library derived from a glioblastoma cell line was screened with five heterologous sera. A library derived from a pilocytic astrocytoma and a library from a glioblastoma were screened with the autologous patients' serum each.
All positive clones were subjected to a secondary screening using the same sera as in the primary screenings. Antigens ACTN4, ING4, U2AF1L1, ZNF232, and HSPH1 were detected by heterologous serum screening of the glioblastoma cell line expression library. Antigens PHF3, GLEA2, TPR, GOLGA1, and KIAA0376 were detected by autologous serum screening of the glioblastoma expression library. Antigens RTN4, CYLN2, and HCLS1 were detected by autologous screening of the pilocytic astrocytoma expression library. The remaining 22 antigens were identified in our previous studies on human intracranial tumors. They were immunogenic in both the primary and the secondary screenings with sera of meningioma patients. Detailed information on the antigens is provided in Table 1 .
The antigen panel was tested for reactivity with 325 sera including 88 sera from glioma patients, 155 sera from patients with other brain pathologies, and 82 sera from donors without known disease. In detail, we analyzed 19 patients with astrocytoma grade 2, 12 with astrocytoma grade 3, 57 with glioblastoma, 35 with meningioma, 20 with pituitary adenoma, 20 with acoustic neurinoma, 20 with cerebral metastases, 20 with multiple sclerosis, 20 with chronic inflammatory demyelinating polyradiculoneuropathy, and 20 with headache (Fig. 1) .
The mean age of glioma patients was 45.7 years and the mean age of controls was 48.6 years. This difference was statistically not significant (Wilcoxon Mann-Whitney test). Likewise, the difference between gender distributions was statistically not significant (Fisher's exact test).
Classification of glioma sera, sera of patients with other brain pathologies, and normal sera. We applied several standard statistical learning methods including NB classifiers, SVM, linear discriminant analysis, or diagonal discriminant analysis to the seroreactivity profiles by using 10-fold cross-validation. Although, in general, all approaches are done comparably well, we only present the results of the NB approach that yielded the most accurate predictions. First, we classified glioma sera versus all other sera including those of patients with other brain pathologies and those of normal donors. The specificity of the NB approach was 92.4%, the sensitivity was 70.1%, and the accuracy was 86.2%. The area under the receiver operator characteristics statistics curve (AUC value) was 0.927. By selecting a different classification threshold, sensitivity and specificity can be balanced. Using a threshold of 1.0, we achieved a specificity of 86.1%, a sensitivity of 85.2, and an accuracy of 85.8%.
Next, we discriminated between glioma sera and normal controls yielding a specificity of 87.8%, a sensitivity of 85.2%, an accuracy of 86.5%, and an AUC value of 0.918. The classification of glioma sera versus other intracranial tumor sera (meningioma, pituitary adenoma, acoustic neurinoma, and intracranial metastases) yielded a specificity of 89.5%, a sensitivity of 86.4%, an accuracy of 88.0%, and an AUC value of 0.95. For the classification of glioma versus meningioma sera, we achieved a sensitivity of 96.6%, a specificity of 80%, an accuracy of 91.9%, and an AUC of 0.954. We obtained comparably good results for the discrimination between glioma sera and nontumor brain pathologies (multiple sclerosis, chronic inflammatory demyelinating polyradiculoneuropathy, and headache). This classification yielded a specificity of 81.7%, a sensitivity of 93.2%, an accuracy of 87.8%, and an AUC value of 0.94. All described classification results were statistically significant (permutation test P < 10 -10 ). In summary, we were able to accurately discriminate between glioma and normal sera, glioma sera and sera of patients with other brain pathologies, and most notably glioma and all other tested sera. Best results were obtained for the classification of glioma versus other intracranial tumors. Exemplarily, details of the classification of glioma versus other intracranial tumors are shown in Fig. 2A and of glioma versus meningioma in Fig. 2B . All results are summarized in Table 2 .
To test the stability of the classification results, we computed for each serum the frequency of correct predictions in the 100 classification runs. The majority of the sera are consistently classified as either correct or false throughout all 100 CV runs as shown in Supplementary Fig. S1 . Thus, the influence of the partition in test and training set is moderate and the classification results are stable. Research. Frequency of antigen reactivities. We compared the frequency of antibody responses of glioma sera and normal sera. On average, we found 4.9 antigens per glioma serum and 3.3 antigens per normal serum, showing a significantly (P < 10 -10 ) elevated antibody response for glioma patients. Next, we compared the frequency of antibody responses of glioma sera and other brain pathologies including intracranial tumors. Likewise, we found a significantly (P < 10 -10 ) decreased reactivity (3.3 antigens per serum) compared with glioma sera. To analyze the frequency of the antibody response within the group of glioma patients, we compared diffuse astrocytoma (WHO II), anaplastic astrocytoma (WHO III), and glioblastoma (WHO grade IV). The average number of antigens declined from 5.37 for WHO grade II glioma to 5.17 for WHO grade III glioma and to 4.63 for glioblastoma. This is consistent with our previous observation on meningioma, indicating that increasing tumor malignancy is associated with a decrease of the frequency of antigen reactivity (1) .
Diagnostic value of antigens to separate glioma sera from other sera. We identified eight antigens that reacted with glioma sera but not with normal sera. From this set of antigens, GLEA2 had the highest frequency in glioma sera (15%). Notably, seven of these antigens also showed reactivity with control sera (that is, sera of patients with other brain pathologies). Most of these antigens react, however, only with few control sera. These findings suggest that each antigen probably will be detected in normal or control sera if the set of tested sera increases (falsepositive antigen occurrences). Balloon plots of the reactivity of antigens in glioma compared with normal and in glioma compared with control sera are shown in Fig. 3A and B.
The above observations raised the question how ''valuable'' each of the 35 antigens is for the classification of glioma versus control sera. For example, is an antigen found in 5% of all glioma sera but not in any normal or control serum more valuable than an antigen detected in 80% of glioma sera but also in 10% of normal and control sera? Mutual information is a suitable measure to answer such a question (14) . In our application, it can be interpreted as the ''value'' of an antigen for a given classification task. We computed the mutual information of each antigen and the four classification tasks mentioned above (glioma versus all, glioma versus normal, glioma versus other intracranial tumors, and glioma versus nontumor brain pathologies). The four mutual information profiles of our antigen set revealed a high correlation between glioma versus all and the other three mutual information profiles (0.86, 0.91, and 0.84). The correlation was only 0.68 between glioma versus normal and glioma versus other intracranial tumors and 0.6 between glioma versus normal and glioma versus nontumor brain pathologies. This implies that antigens with a high information considering glioma versus normal do not necessarily provide much information for the classification of glioma versus other diseases. Notably, we computed a high correlation (0.83) between glioma versus other intracranial tumors and glioma versus nontumor brain pathologies, indicating that most antigens contain similar information for these classification tasks. The four mutual information profiles of each antigen are shown in Fig. 4 .
The comparison of the mutual information profiles indicates that some antigens (KIAA0376 or ING4) provide almost the same information on the four different tasks, whereas other antigens are more valuable for only one or two of the four classification tasks. C13orf24, for example, entails much information on glioma versus other tumors and glioma versus nontumor brain pathologies, whereas the antigen SART1 is the most valuable antigen for glioma versus normal.
Discussion
One of the foremost goals in human cancer research is the identification of biomarkers to improve diagnosis of cancer, especially while the tumor is still in its early stages of development. Few studies report single glioma antigens Fig. 2 . Classification results. A, result of the discrimination between glioma sera is indicated by ''0''and other intracranial tumor sera is indicated by ''1.'' B, result of the discrimination between glioma sera is indicated by ''0''and meningioma sera is indicated by ''1.'' X axis, indices (numbers) of the tested sera;Yaxis, logarithm of the output Q of the NB classifier for the tested sera. If this value is smaller than 0 (horizontal line) for a tested serum, then it is classified as a glioma serum; otherwise, it is classified as nonglioma serum.
including BAGE, GAGE1, MAGE1, p53, BCR-ABL, Melan-A, and tyrosinase s, most of them recognized by T-cell response (15 -18) . Screening with autologous or allogenic human sera also detected glioma antigens including MCM3, SOX6, endostatin, TEGT (Bax inhibitor1), and SON (19 -22) . However, none of these antigens has been evaluated for its reactivity against serum antibodies with a large number of patients' sera. Previously, we identified proteins PHF3, GLEA2, and GLEA1 (KIAA0376) that trigger an antibody response in 57%, 43%, and 24%, respectively, of glioma patients (23 -25) . Nevertheless, even the latter antigens do not suffice to perform an accurate glioma classification.
Most recently, others and we provided evidence that sophisticated antibody signatures offer a powerful tool for noninvasive cancer classification. Besides SEREX, other methods have been used successfully to identify autoantibody signatures. A recent proof-of-principle study used a reversed capture autoantibody microarray on a limited number of samples. A cell lysate is applied to monoclonal antibodies bound to glass surface. Subsequently, serum autoantibodies can bind to native antigens of the immobilized cell lysates (26) . A more commonly used approach is the T7 phage epitope screening that uses libraries expressed on the capsid surface of T7 phages. This method was already applied for various cancers including prostate cancer, lung cancer, and ovarian cancer (3 -7). Wang et al. (3) were able to discriminate between sera of prostate tumors and sera of a control group with a specificity of 88.2% and sensitivity of 81.6%. Chen et al. (4) separated sera of lung adenocarcinoma patients from healthy controls with a specificity of 86% and a sensitivity of 85%. Sera of patients with non-small lung cancer were separated from normal sera with a specificity of 95% and a sensitivity of 90% (5) . A study on ovarian cancer reached only an average sensitivity of 32% at a specificity of 94% (6), whereas a study on epithelial ovarian cancer patients yielded a value of 0.86 for AUC without providing the values for specificity and sensitivity (7) . Whereas most studies on seroreactivity profiling compared tumor sera with a single group of control sera, our study included several control groups of the same organ. To distinguish between glioma sera and the different groups of control sera, we employed several classification methods including SVM and NB approaches. We were able to differentiate glioma sera from all other sera with high specificity and sensitivity. Glioma sera were best separable from other intracranial tumor sera, especially from meningioma sera.
Most antigens with high mutual information values (Table 1) have not been clearly associated with glioma development yet. NOTE: Summary of the different classification results including the used classification method, number of sera of the respective classes, specificity, sensitivity, accuracy, AUC, and P value calculated with permutation tests. Fig. 3 . A, number of antigens that reacted with serum antibodies of glioma patients and healthy individuals. Antigens below the diagonal line react more frequently with glioma sera; antigens above the diagonal line react more frequently with normal sera. The rightmost antigen, SART1, reacts with 65% of glioma and 13% of normal sera. The size of the circles reflects the number of antigens reactive against a given number of sera. It can be clearly seen that most antigens react more frequently with glioma than with normal sera. B, number of antigens that reacted with serum antibodies of glioma patients and patients with other brain pathologies including other intracranial tumors. Several antigens (e.g. HSPH1) below the diagonal line react more frequently with glioma sera than with sera of patients with other brain pathologies.
SART1, which is most valuable for the separation between glioma and normal sera, is essential for the assembly of spliceosomes. Depletion of SART1 leads to an impaired premRNA processing of genes essential for cell division (27) . An altered SART1 expression in glioma may be associated with the highly aberrant karyotype of this tumor. BRAP plays a role in the Ras/mitogen-activated protein kinase signaling (28) . RTN4 is a potent neurite outgrowth inhibitor and plays a role in autoimmune demyelination (29) . NKTR is highly expressed on the surface of natural killer cells where it facilitates tumor cell recognition by a MHC-independent pathway (30) . Expression of NKTR on the surface of glioma cells may interfere with tumor cell recognition. For experts in the field of statistical learning, we note that we additionally applied filter and wrapper subset selection approaches. However, these methods did not show better performance than the classification with the complete data set. Moreover, we used the so-called mutual information to measure the diagnostic information content of each antigen for a given classification task (that is, the discrimination between glioma sera and normal sera). Mutual information enabled us to determine the strength of the association between an antigen and a certain disease or a class of diseases.
Our results provide clear evidence that seroreactivity patterns combined with standard statistical learning methods allow for an accurate discrimination between glioma and other brain pathologies even between glioma and other intracranial tumors. The discrimination between a tumor and other pathologies of the same organ is a necessary prerequisite for any future approach that will apply antigen reactivity patterns for tumor diagnosis. Although our study substantiates the feasibility of a seroreactivity-based diagnosis for glioma, this finding needs to be ascertained for each tumor type separately. Based on our approach, prospective studies can also address the question whether seroreactivity profiling may permit identification of tumors earlier than imaging technologies. It is likely that a tumor mass becomes visible for the immune system long before it reaches a size that can be picked up by imaging technology. Future studies on seroreactivity patterns may not only allow for discrimination between tumor types of the same organ but also between different grades of one tumor type. In the long term, it is conceivable that seroreactivity patterns may indicate how to optimize cocktail approaches against multiple targets in therapeutic trials. However, therapeutic approaches require detailed information on the biology of each immunogenic antigen.
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